Current in vitro technologies are not capable to support for long-term ex vivo the growth of isolated GLP-1 producing-cells
Urva et al., The novel GIP, GLP- 1 and glucagon receptor agonist retatrutide delays gastric emptying, Diabetes Obes
GLP-1s may not be suitable for people who: Have a history of pancreatitis Have certain thyroid conditions (e.g., medullary thyroid cancer) Are pregnant or breastfeeding (depending on the specific medication) Have severe gastrointestinal conditions, like gastroparesis GLP-1 receptor agonists, including Tirzepatide, have been shown to lead to significant weight loss, with many people losing 10-15% of their body weight over time
The Dose-Response Relationship The trial enrolled adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related health condition, excluding people with type 2 diabetes
Injectable: Key Differences While both forms contain semaglutide, there are important practical differences patients should understand before choosing between them
3,12 The overall purpose of the activity of these hormones is to ensure that all biological processes throughout the body are provided with adequate energy in the form of ATP for them to occur, by promoting anabolism (in the case of insulin) and catabolism (in the case of glucagon) of carbohydrates and fats in tissues as required
